Who Supplies Cabozantinib to India from TAIWAN

Importing finished pharmaceutical formulations containing Cabozantinib into India requires compliance with the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The Central Drugs Standard Control Organisation (CDSCO) mandates that all imported drugs be registered and approved before entry. The registration process involves submitting Form 40 or 41 to CDSCO, along with a No Objection Certificate (NOC) from the Ministry of Health and Family Welfare. The timeline for import drug registration varies but typically ranges from 6 to 12 months, depending on the completeness of the application and regulatory workload. For Cabozantinib formulations under HS Code 30049099, specific requirements include providing a Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificates, stability data (preferably ICH Zone IV), and a Free Sale Certificate from the country of origin. Additionally, an Importer Exporter Code (IEC) from the Directorate General of Foreign Trade (DGFT) is mandatory for all importers.

Imported pharmaceutical formulations containing Cabozantinib must undergo quality testing at CDSCO-approved laboratories in India. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, preferably from ICH Zone IV studies, should be provided to demonstrate the product's shelf-life under Indian climatic conditions. Port inspection by customs drug inspectors is mandatory to verify the authenticity and quality of the imported drugs. If a batch fails quality testing, it may be rejected, leading to re-exportation or destruction, depending on the regulatory decision.

Between 2024 and 2026, the CDSCO has implemented several regulatory updates affecting the import of finished pharmaceutical formulations. The Production Linked Incentive (PLI) scheme, introduced to boost domestic manufacturing, has led to increased scrutiny of imported formulations, including those containing Cabozantinib. Bilateral agreements between India and Taiwan have facilitated smoother trade relations, but they also require adherence to mutual Good Manufacturing Practice (GMP) standards and other compliance measures. These developments aim to balance the promotion of domestic production with the need for essential imported medicines.

India imports finished Cabozantinib formulations primarily due to the unavailability of domestically manufactured equivalents. The patented nature of Cabozantinib formulations and the specialized dosage forms required for certain cancers contribute to this dependency. The market size for Cabozantinib in India is growing, driven by increasing cancer incidence and the need for advanced treatments. However, the reliance on imports poses challenges related to cost, supply chain stability, and regulatory compliance.

The import duty structure for finished pharmaceutical formulations under HS Code 30049099 includes a Basic Customs Duty (BCD) of 10%, an Education Cess of 2%, a Secondary Higher Education Cess of 1%, and a Countervailing Duty (CVD) of 6%. The Social Welfare Surcharge (SWS) is 10%. The Integrated Goods and Services Tax (IGST) is 12%. There are no exemptions or concessional rates for imports from Taiwan. The total landed duty percentage is approximately 17.10%.

India sources finished Cabozantinib formulations from Taiwan due to the competitive advantages offered by Taiwanese manufacturers, including adherence to international quality standards, advanced manufacturing technologies, and the ability to supply specialized dosage forms not readily available domestically. While other countries like China, Germany, and the United States also supply Cabozantinib formulations, Taiwan's consistent quality and reliability make it a preferred source. Taiwan's share in the Indian market for Cabozantinib formulations is significant, reflecting its strong position in the pharmaceutical export sector.

India imports finished Cabozantinib formulations from Taiwan due to the unavailability of domestically manufactured equivalents, the patented nature of the drug, and the need for specialized dosage forms required for certain cancers. Taiwan's adherence to international quality standards and its ability to supply these specialized formulations make it a preferred source for Indian importers.

When compared to other potential sources like China, Germany, and the United States, Taiwan offers competitive pricing, high-quality manufacturing, and reliable supply chains. While other countries may also supply Cabozantinib formulations, Taiwan's consistent quality and adherence to international standards provide a unique advantage for Indian importers.

Indian importers face several supply chain risks when sourcing finished Cabozantinib formulations from Taiwan, including single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, importers should consider dual-sourcing strategies, maintain adequate inventory levels, and establish strong relationships with suppliers.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain buffer stocks to manage supply chain disruptions.
3. 3Payment Terms: Negotiate favorable payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Supplier Qualification: Conduct thorough due diligence to ensure supplier reliability and compliance with regulatory standards.
5. 5Regulatory Compliance: Stay updated on regulatory changes and ensure all imports meet CDSCO requirements.

Implementing these strategies can enhance the security and efficiency of sourcing Cabozantinib formulations from Taiwan.

1. 1DGFT Importer Exporter Code (IEC): Obtain an IEC from the Directorate General of Foreign Trade.
2. 2CDSCO Form 40/